Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,001 - 1,050 out of 11,188

Document Document Title
WO/2006/122250A3
The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.  
WO2005074603A3
A compound of Formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.  
WO/2006/117664A1
Compounds of formula (I); wherein - R1 and R2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, ...  
WO2006028963A3
The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders ...  
WO/2006/117743A1
The present invention relates to substituted aromatic compounds, which have PPAR modulating activity, and hence can be used as anti-diabetic agents. Compounds described herein can be used as peroxisome proliferation activated receptor (P...  
WO2006091848A9
The present invention provides an isolated linezolid (1) impurity, bis-linezolid (4), preparation thereof and its use as a reference standard.  
WO/2006/116007A2
Disclosed is a method of making 2-substituted-2-halo-1,3-propanediols via reduction of corresponding malonate compounds. Also disclosed is a method of making 2-substituted-2-halo-1,3-dicarbamate compounds (such as halo derivatives of fel...  
WO/2006/114274A1
Compounds of formula (I) or a pharmaceutiically acceptable derivative thereof: wherein X, Z, Y', Y'', R1 ,R2a, R2b, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions ...  
WO2005041899A3
The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structur...  
WO2005099353A3
The present invention provides a novel process for preparation of 5-aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials including linezolid. Thus linezolid is prepared by a) reacting 3-fluoro-4-morp...  
WO/2006/111285A3
The invention relates to novel imino-oxazolidines of formula (I), to methods for producing same, and to the use thereof for treating and/or preventing diseases as well as for producing drugs for treating and/or preventing diseases, in pa...  
WO2006083271A3
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...  
WO/2006/111285A2
The invention relates to novel imino-oxazolidines of formula (I), to methods for producing same, and to the use thereof for treating and/or preventing diseases as well as for producing drugs for treating and/or preventing diseases, in pa...  
WO/2006/108491A1
An improved process for preparing oxazole nitriles of formula (I) in which Ar is aryl or heteroaryl and Rl is H or alkyl , which comprises reacting a corresponding oxazole chloride of formula (II) in which Ar and Rl are as defined above,...  
WO2006091731A3
The present invention provides improved methods of converting R-N-(4-morpholiyl- 3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) to the intermediate S-N-(4- morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) that ...  
WO/2006/110477A3
The invention discloses aromatic amides and sulfonates to treat or prevent type 2 diabetes mellitus (T2DM), the pathological consequences of T2DM, to inhibit amyloidosis or to prevent death of β-cells of the pancreas.  
WO/2006/108671A1
3,4-Dihydro-benzo[e][1 ,3]oxazin-2-ones, e.g. which are mediators of human macrophage migration inhibitory factor activity.  
WO/2006/110155A1
Novel crystalline forms of Linezolid, designated as Form TIII, Form V, Form VI, Form IX, Form X, Form XII, Form XIV, Form XVII, and Form XVIII, are disclosed. The novel crystalline forms are characterized by powder X-ray diffraction, FTI...  
WO/2006/108493A1
A process for preparing oxazole carboxylic esters of the formula (I) in which Ar is aryl or heteroaryl, Rl is H or alkyl and R2 is alkyl or aryl, which comprises converting an oxazole nitrile of the formula (II) in which Ar and Rl are as...  
WO/2006/108591A1
The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schiz...  
WO/2006/109817A1
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1 represents a branched alkyl group having 3 to 9 carbon atoms or the like; R2 represents a 6-membered heteroaryl group having 1 or 2 n...  
WO/2006/106437A3
The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinas...  
WO/2006/106437A2
The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinas...  
WO/2006/103057A1
The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, (I), wherein A1 is CH C(C...  
WO/2006/104594A3
Described herein are compounds that have a spiro structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, and pharmac...  
WO/2006/105051A2
Disclosed herein are methods for synthesizing diketopiperazines with enantiomeric excess by inducing cyclization of an α- keto acid with an acid catalyst.  
WO2006059245A3
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, ...  
WO/2006/104755A3
A pretreatment composition for treating a substrate to be subjected to forming a relief pattern thereon by exposure to actinic radiation, the pretreatment composition comprising: (a) at least one compound having Structure (VI), wherein, ...  
WO/2006/105051A3
Disclosed herein are methods for synthesizing diketopiperazines with enantiomeric excess by inducing cyclization of an α- keto acid with an acid catalyst.  
WO/2006/103045A1
The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3 -receptor ligands, Formula (I), ...  
WO/2006/105217A2
Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, ...  
WO/2006/102674A2
Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivative are described, as are pharmaceutical compositions containing these compound and their use for preparing medicaments for the treatment of hypercholesterolemia  
WO2005013914A8
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...  
WO/2006/096994A1
The present invention relates generally to perfluoroalkyl chiral auxiliary compounds and methods of manufacture. These compounds have the functionality to effectively support the synthesis of chiral compounds in single reactions, high-th...  
WO/2006/094770A2
The invention relates to an apparatus for the final processing of a forming tool (5, 7) for a sheet-metal body part, in which, in a first operation for identifying a surface region (45) of a tool surface (9, 11) to be reworked, a sheet-m...  
WO/2006/096584A1
The present invention relates to processes for the preparation of substituted benzoxazole compounds, and in particular 2-(3-fluoro-4-hydroxy-phenyl)-7-vinyl- benzoxazol-5-ol. The processes include the vinylation of a substituted benzoxaz...  
WO/2006/094682A1
This invention is concerned with compounds of the formula (I) wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical co...  
WO/2006/094923A1
The invention relates to a sensor element for determining particles in gaseous mixtures, in particular for carbon black sensors. The element comprises a ceramic sensor body, into which a heating element is integrated, in addition to a fi...  
WO2006034296A3
The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.  
WO/2006/094602A1
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, and q have the designations cited in patent claim 1. Said compounds can be used, inter alia, for the treatment of tumours.  
WO/2006/096591A1
The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3- fluoro-4-hydroxyphenyl)-7-vinyl-l,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abno...  
WO/2006/096624A1
The present invention provides processes for the purification of substituted benzoxazole compounds of formla (I), and in particular 2-(3-fluoro-4-hydroxy-phenyl)-7-vinyl- benzooxazol-5-ol. The processes include recrystallizing the compou...  
WO/2006/094236A1
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treatin and/or preventing a wide variety of diseases and disorders...  
WO/2006/092074A1
A compound of the formula (I) in which X and Y are selected as defined in the description. The compounds have cooling properties and are useful in, for example, foodstuffs , dentifrices and cosmetics .  
WO/2006/093354A1
Disclosed are a novel production intermediate of (S)-2-[3-(N-&lcub [4-(4-fluorophenoxy)phenyl]methyl&rcub carbamoyl)-4-methoxyphenylmethyl]butanoic acid (compound 1), and a method for producing the same. Specifically disclosed is benzyl ...  
WO2006066133A3
Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formula: wherein the variables are as defined herein.  
WO/2006/090792A1
A haloalkylsulfonanilide derivative represented by the formula (I): &lcub wherein R1 represents haloalkyl; R2 represents H, alkylcarbonyl, optionally substituted phenylcarbonyl, alkoxycarbonyl, optionally substituted phenoxycarbonyl, opt...  
WO/2006/091848A2
The present invention provides an isolated linezolid (1) impurity, bis-linezolid (4), preparation thereof and its use as a reference standard.  
WO/2006/090235A1
The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, arylox...  
WO/2006/091731A2
The present invention provides improved methods of converting R-N-(4-morpholiyl- 3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) to the intermediate S-N-(4- morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) that ...  

Matches 1,001 - 1,050 out of 11,188